RxDoctor Payments Data

Shira McMahan, DO

Neurology · Stuart, FLNPI 1124339247

Payments from drug & device makers

$372in general payments, 2019–2025

Across 13 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$118
  • Argenx US, Inc.$73
  • Neurelis, Inc.$49
  • MDD US Operations, LLC$33
  • AstraZeneca$30
  • UCB, Inc.$21
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$35896%
  • Education$134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$372 in reported general payments places this provider in the 25th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$286,279
Medicare patients
687
Services billed
22,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate11$104,421
NuplazidPimavanserin Tartrate14$100,039
VumerityDiroximel Fumarate11$93,155
Aimovig AutoinjectorErenumab-Aooe19$24,015
Emgality PenGalcanezumab-Gnlm15$19,047
Ajovy AutoinjectorFremanezumab-Vfrm16$14,877
RytaryCarbidopa/Levodopa13$13,060
UbrelvyUbrogepant13$12,177
Dalfampridine ErDalfampridine17$10,200
Carbidopa-LevodopaCarbidopa/Levodopa288$8,223
RivastigmineRivastigmine Tartrate68$5,006
Lacosamide33$4,766
Rasagiline Mesylate21$4,588
AmantadineAmantadine Hcl59$4,305
Gabapentin235$4,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$19$197,57622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,434 neurology providers in Florida.

Other neurology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →